Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term. | March 23, 2023
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody against SARS-CoV.
Form 10-K Passage BIO, Inc For: Dec 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
$ million
Gross to Net Adjustment
19% - 20%
21% - 21.5%
Conference Call
Puma Biotechnology will host a conference call to report its fourth quarter and full year 2022 financial results. | March 2, 2023
$9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launchVTAMA. | February 13, 2023